Skip to main content

Table 1 Sampling distributions from empiric studies for model input parameters

From: Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model

Parameter

Point Estimate a

Range a

References

Percent of Cases Reporting Symptomsb at Time of Testing

67%

54-84%

12–15

Percent of Non-Cases Reporting Symptomsb at Time of Testing

32%

18-53%

12, 13, 15

Antigen Test Sensitivity Among Symptomaticb Cases

80%

64-94%

12, 13, 15–17

Antigen Test Sensitivity Among Asymptomatic Cases

55%

41-69%

12, 13, 15–18

Antigen Test Specificity Among Symptomaticb Non-Cases

99.7%

98.9-100%

12, 13, 15–17

Antigen Test Specificity Among Asymptomatic Non-Cases

99%

98.0-100%

12, 13, 15–18

NAAT Sensitivity for viral RNA Detection (including previously infectious persons) c

100%

  

NAAT Specificity c

100%

  

Sensitivity of Repeat Antigen Test (After Initial Negative Antigen Result)

18%

10-29%

13

Specificity of Repeat Antigen Test (After Initial Negative Antigen Result)

100%

99.8-100%

13

Proportion of Asymptomatic Non-Cases Reporting Recent Close Contact Exposure at Time of Testing

27%

9-45%

12,13

Mean Time Elapsed Between Sampling and Return of NAAT Result (days)c

3

1-5

 
  1. Abbreviations: NAAT – Nucleic Acid Amplification Test
  2. a Parameter values sampled from a triangular distribution with the modal value defined by the point estimate and upper and lower bounds defined by the range
  3. b Symptom criteria varied across reports used to estimate parameter values but were generally defined as the presence of one or more COVID-19 symptom at the time of testing
  4. cModel assumption
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us